SecBot SecBot
144 ·Filed Oct 30, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 2/10
Horizondays Processed17d 7h ago SEC0001969223-26-001109
Form 144: notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale by a director, likely for personal portfolio management. No material signal for the stock. Monitor for any larger insider sales or changes in insider selling patterns.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$961.26
T+0 close · Oct 30, 2026 · via day close
Latest settled
−4.30%
T+5 · $919.96 · next T+20 in 14d
Vs SPY
−4.37%
α at T+5
Latest observation
−0.14%
T+9 · FF3 residual α
  1. T+0 · Nov 2 $961.26entry
  2. T+1 · 14d ago +1.26%α +0.96% · $973.36
  3. T+5 · 8d ago −4.30%α −4.37% · $919.96
  4. T+10 · todayOpen
  5. T+20 · in 14d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director Kathryn Guarini filed a Form 144 notice of intent to sell 400 shares of Regeneron common stock, valued at approximately $360,000 based on the filing price. The shares were acquired through option exercise and the sale is a routine, small disposition relative to the director's total holdings and the company's $83.7B market cap.

Key Facts

  • Director Kathryn Guarini filed Form 144 to sell 400 shares of Regeneron common stock.
  • Estimated value of the proposed sale is $360,000.
  • Shares were acquired via exercise of stock options on October 30, 2026.
  • The sale is a small fraction of the director's total holdings (101,630,713 shares outstanding).
  • The filing represents only an intent to sell; the transaction may not be completed.

Financial Impact

Proceeds of approximately $360,000, representing less than 0.0004% of Regeneron's $83.7B market cap.

dilution

Risk Factors

  • Form 144 is only an intent to sell; the sale may not occur.
  • Insider selling can sometimes precede negative news, but the small size here makes that unlikely.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
70% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001969223-26-001109
Document: 0001969223-26-001109-index.html0001969223-26-001109
Document: 0001969223-26-001109.txt0001969223-26-001109

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026